Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $7.20 Analyst target: $23.33 Upside: 224.03%
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.